Oncology Penny Stocks

US-listed oncology penny stocks priced $0.50 to $5, ranked by today's percentage change. Cancer-focused drug developers, immuno-oncology, radioligand therapy, ADC platforms, CAR-T, and oncology-diagnostics plays. Updated intraday.

Data as of 7/15/2026 1:40:34 AM · Intraday prices · 106 penny stocks in theme
#SymbolCompanySectorPriceDay ChgVolume
1SHPHShuttle Pharmaceuticals Holdings, Inc. Common StockHealthcare$3.8320+40.88%52.3M
2ACTUActuate Therapeutics, Inc. Common stockHealthcare$1.8170+18.00%2.6M
3ZCMDZhongchao Inc. Class A Ordinary SharesHealthcare$1.6700+15.56%375K
4PMVPPMV Pharmaceuticals, IncHealthcare$1.4040+11.33%1.1M
5PCSAProcessa Pharmaceuticals, Inc. CommonHealthcare$2.2100+11.17%106K
6INMBINmune Bio Inc. Common stockHealthcare$1.9750+8.87%991K
7ACRVAcrivon Therapeutics, Inc. Common StockHealthcare$2.0750+8.33%962K
8BOLTBolt Biotherapeutics, Inc. Common StockHealthcare$4.0500+5.29%29K
9PSTVPLUS THERAPEUTICS, Inc. Common StockHealthcare$4.2750+4.32%361K
10ANIXAnixa Biosciences, Inc.Healthcare$3.1800+3.76%178K
11ANIXAnixa Biosciences, Inc.Healthcare$3.1800+3.76%178K
12PPCBPropanc Biopharma, Inc. Common StockHealthcare$1.5900+3.75%90K
13LITSLite Strategy, Inc. Common StockHealthcare$0.9950+3.62%114K
14ZNTLZentalis Pharmaceuticals, Inc. Common StockHealthcare$4.8490+3.25%811K
15MBRXMoleculin Biotech, Inc.Healthcare$2.2100+3.17%118K
16ICCMIceCure Medical Ltd. Ordinary SharesHealthcare$3.6200+3.11%90K
17PHIOPhio Pharmaceuticals Corp. Common StockHealthcare$1.0400+3.00%101K
18OKUROnKure Therapeutics, Inc. Class A Common StockHealthcare$4.2250+2.92%77K
19ALLRAllarity Therapeutics, Inc. Common StockHealthcare$1.1950+2.65%95K
20BCABBioAtla, Inc. Common StockHealthcare$3.9900+2.56%62K
21OSTXOS Therapies IncorporatedHealthcare$1.6690+2.47%439K
22MAIAMAIA Biotechnology, Inc.Healthcare$1.4550+2.12%1.4M
23ALXOALX Oncology Holdings Inc. Common StockHealthcare$2.0550+2.03%692K
24CLRBCellectar Biosciences INC NEWHealthcare$2.7040+1.90%43K
25ENGNenGene Therapeutics Inc. Common StockHealthcare$1.8600+1.61%1.3M
26IMNNImunon, Inc. Common StockHealthcare$1.9260+1.53%15K
27LUCDLucid Diagnostics Inc. Common StockHealthcare$1.0080+0.90%675K
28LNAILunai Bioworks Inc. Common StockHealthcare$2.8940+0.71%29K
29INTSIntensity Therapeutics, Inc. Common stockHealthcare$4.9810+0.41%53K
30BIAFbioAffinity Technologies, Inc. Common StockHealthcare$0.7060+0.33%157K
31SRTSSensus Healthcare, IncHealthcare$3.0150+0.32%4K
32HURATuHURA Biosciences, Inc. Common StockHealthcare$2.33100.00%535K
33BOLDBoundless Bio, Inc. Common StockHealthcare$2.49500.00%299K
34AIDX20/20 Biolabs, Inc. Common StockHealthcare$0.56700.00%195K
35CTXRCitius Pharmaceuticals Inc. CommonHealthcare$0.54500.00%174K
36CGENCompugen LtdHealthcare$2.22100.00%132K
37APVOAptevo Therapeutics IncHealthcare$4.35500.00%76K
38CRISCuris IncHealthcare$4.69500.00%72K
39PMCBPharmaCyte Biotech, Inc. Common StockHealthcare$0.69000.00%63K
40YDESYD Bio Limited Ordinary SharesHealthcare$2.11000.00%60K
41SNTISenti Biosciences Holdings, Inc. Common StockHealthcare$0.95400.00%57K
42SBFMSunshine Biopharma Inc.Healthcare$1.93300.00%48K
43CELUCelularity Inc. Class A Common StockHealthcare$0.76000.00%48K
44ESLAEstrella Immunopharma, Inc. Common StockHealthcare$0.81000.00%39K
45BDMDBaird Medical Investment Holdings Ltd Ordinary ShareHealthcare$1.11000.00%36K
46CTORCitius Oncology, Inc. Common StockHealthcare$0.68500.00%33K
47BGMSBio Green Med Solution, Inc. Common StockHealthcare$0.89400.00%29K
48INDPIndaptus Therapeutics, Inc. Common StockHealthcare$2.62000.00%22K
49XBIOXenetic Biosciences, Inc.Healthcare$2.97500.00%21K
50LSTALisata Therapeutics, Inc. Common StockHealthcare$3.73000.00%20K

Trading Sub-$5 Oncology

Oncology is the most catalyst-rich corner of biotech. Cancer trials produce frequent readouts, FDA decisions are highly visible, and a single Phase 1/2 hit can rerate a company 500-1,500%. The flip side: clinical holds and failed primary endpoints can wipe out 60-90% in a session. This is binary-event trading at its purest.

  • ASCO & ESMO conferences: major oncology conferences (May, September, June) are catalyst-dense windows. Abstracts publish 3-4 weeks before the meeting.
  • PDUFA dates: FDA action dates for cancer drugs are scheduled events — visible on FDA.gov.
  • Trial readout calendar: companies pre-announce expected readout windows; the windows themselves are the trade setup.
  • Indication breadth: companies with multiple cancer indications are more durable than single-asset plays. Platform technologies (ADCs, radioligands, bispecifics) command premiums.
  • Survival endpoints: overall survival (OS) is the gold standard; surrogate endpoints (PFS, response rate) are weaker. Pay attention to which the trial used.
  • Partnership leverage: a Big Pharma licensing deal can revalue a sub-$5 oncology company overnight.
  • Dilution constant: oncology development is expensive. Most sub-$5 names raise capital every 6-18 months — see our dilution explainer.
  • Halt risk on readout days: volatility halts (LUDP) are routine on trial-data days — see our halt guide.

See also: biotech penny stocks (broader), genomics penny stocks, penny stocks under $1.